Skip to main content

Table 8 Baseline viral hepatitis serology, safety population

From: Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia

Patients n/N (%)
  ASAQ AL  
Study-T (>5 years) N = 496 N = 502 Total
HBV sAg positive 73/457 (15.9) 70/467 (14.9) 143/924 (15.5)
HBV anti-HBVc positive # 4/73 (5.5) 2/70 (2.8) 6/143 (4.2)
HCV antibody positive 18/455 (4.0) 19/466(4.1) 37/921 (4.0)
HEV anti-IgM positive* 0/33 (0) 0/34(0) 0/67 (0)
  ASAQ AL  
Study-E (6-59 months) N = 149 N = 150 Total
HBV sAg positive 18/148 (12.1) 18/150 (12.0) 36/298 (12.1)
HBV anti-HBVc positive # 1/18 (5.5) 1/18 (5.5) 2/36 (5.5)
HCV antibody positive 7/147 (4.8) 4/148 (2.7) 11/295 (3.7)
HEV anti-IgM positive* 0/5 (0) 0/7 (0) 0/12 (0)
  1. HBV Hepatitis B Virus, HCV Hepatitis C Virus, HEV Hepatitis E Virus, Ag antigen.
  2. Displayed are percentages of patients who tested positive among those with available test results.
  3. # anti-HBVc was assessed for HBV sAg positive patients.
  4. * HEV anti-IgM was assessed for patients with elevated AST or ALT (values 2× upper limit normal range) at any point during study participation, and/or any AE “hepatotoxicity” among Study-T participants.